Gestamp Automocin Sa Stock Current Valuation
| 7GA Stock | 2.61 0.08 3.16% |
Valuation analysis of Gestamp Automocin helps investors to measure Gestamp Automocin's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Gestamp Automocin's price fluctuation is out of control at this time. Calculation of the real value of Gestamp Automocin is based on 3 months time horizon. Increasing Gestamp Automocin's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Gestamp Automocin's intrinsic value may or may not be the same as its current market price of 2.61, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.61 | Real 0.0 | Hype 0.0 | Naive 2.63 |
The intrinsic value of Gestamp Automocin's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gestamp Automocin's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gestamp Automocin SA helps investors to forecast how Gestamp stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gestamp Automocin more accurately as focusing exclusively on Gestamp Automocin's fundamentals will not take into account other important factors: Gestamp Automocin SA Company Current Valuation Analysis
Gestamp Automocin's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Gestamp Automocin Current Valuation | 3.43 B |
Most of Gestamp Automocin's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gestamp Automocin SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Gestamp Automocin SA has a Current Valuation of 3.43 B. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Gestamp Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gestamp Automocin's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gestamp Automocin could also be used in its relative valuation, which is a method of valuing Gestamp Automocin by comparing valuation metrics of similar companies.Gestamp Automocin is currently under evaluation in current valuation category among its peers.
Gestamp Fundamentals
| Current Valuation | 3.43 B | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 0.20 X | |||
| Revenue | 8.09 B | |||
| Gross Profit | 3.44 B | |||
| EBITDA | 1.01 B | |||
| Net Income | 155.38 M | |||
| Total Debt | 2.65 B | |||
| Cash Flow From Operations | 827.39 M | |||
| Market Capitalization | 19.86 M | |||
| Total Asset | 8.64 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 8.64 B |
About Gestamp Automocin Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gestamp Automocin SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gestamp Automocin using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gestamp Automocin SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Gestamp Stock Analysis
When running Gestamp Automocin's price analysis, check to measure Gestamp Automocin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gestamp Automocin is operating at the current time. Most of Gestamp Automocin's value examination focuses on studying past and present price action to predict the probability of Gestamp Automocin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gestamp Automocin's price. Additionally, you may evaluate how the addition of Gestamp Automocin to your portfolios can decrease your overall portfolio volatility.